Benign prostatic hyperplasia. Part 2--management.
Wilt
Timothy J
TJ
Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0), Minneapolis, MN 55417, USA. tim.wilt@med.va.gov
N'Dow
James
J
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D016587:Antimutagenic Agents / Q000627:therapeutic use; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D013677:Medical Laboratory Science; D008517:Phytotherapy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000628:therapy*
D000317:Adrenergic alpha-Antagonists; D016587:Antimutagenic Agents; D042944:Cholestenone 5 alpha-Reductase